Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 209

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 209
---
 announcement, whether written or oral, from any person or group of persons other than the Purchaser (or an affiliate of the Purchaser or any person acting jointly or in concert with the Purchaser) 
 relating to any:                                                                                                                                                                                                                                         |

| (i) | direct or indirect sale, disposition, issuance or acquisition of shares or other equity interests (or                                                                                                                                                    
 securities convertible into or exercisable for such shares or interests) that, when taken together with any securities of the Company held by the proposed acquiror, and any person acting jointly or in concert with such acquiror and assuming the     
 conversion of any convertible securities held by the proposed acquiror and any person acting jointly or in concert with such acquiror, would constitute beneficial ownership representing 20% or more of any class of equity or voting securities of the 
 Company or its Subsidiary;                                                                                                                                                                                                                               |

| (ii) | any direct or indirect sale, disposition, acquisition or purchase (or any lease, long-term supply agreement,                                                                                                                                             
 joint venture or other arrangement having the same economic effect as a sale, disposition, acquisition or purchase) of assets of any member of the Company (including, without limitation, the shares of any subsidiary) representing 20% or more of the 
 consolidated assets of the Company and its Subsidiary;                                                                                                                                                                                                   |

| (iii) | an amalgamation, arrangement, share exchange, merger, business combination, consolidation, recapitalization or 
 other similar transaction involving the Company or its Subsidiary;                                             |

| (iv) | any take-over bid, tender offer, exchange offer, treasury issuance,                                                                                                                                           
 re-capitalization or other similar transaction involving the Company that, if consummated, would result in a person or group of persons acting jointly or in concert acquiring beneficial ownership of 20% or 
 more of any class of equity or voting securities of the Company and assuming the conversion of any convertible securities held by the person or group of persons acting jointly or in concert; or             |

| (v) | any other announcement, transaction or series of transactions involving the Company or its Subsidiary that 
 would have a similar effect as the foregoing;                                                              |

A-5

| (d) | “affiliate” has the meaning ascribed thereto in National Instrument 45-106 – Prospectus Exemptions; |

| (e) | “Agreement” means this arrangement agreement among Parent, the Purchaser, XRC and the                                                            
 Company (including